Chimerix (STU:CXF) Short-Term Debt : €0.00 Mil (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Chimerix Short-Term Debt?

Chimerix's Short-Term Debt for the quarter that ended in Mar. 2024 was €0.00 Mil.

Chimerix's annual Short-Term Debt declined from Dec. 2021 (€12.39 Mil) to Dec. 2022 (€0.00 Mil) but then stayed the same from Dec. 2022 (€0.00 Mil) to Dec. 2023 (€0.00 Mil).

Chimerix Short-Term Debt Historical Data

The historical data trend for Chimerix's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chimerix Short-Term Debt Chart

Chimerix Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt

Get a 7-Day Free Trial

12.39

Chimerix Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Debt	Get a 7-Day Free Trial															-	-	-	-	-

Chimerix Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Chimerix Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Chimerix's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Chimerix (STU:CXF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimerix Inc (STU:CXF) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

CMRX:USA CXF:Germany

Address

2505 Meridian Parkway, Suite 100, Durham, NC, USA, 27713

Website

https://www.chimerix.com

Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through license agreements and a federal contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA) for research and advanced development of drugs to treat various human diseases. The company operates only in one business segment namely pharmaceuticals.

Chimerix (STU:CXF) Headlines

No Headlines